Agios Posts $1.09 Per-Share Q3 Loss as Mitapivat Decision Slips to February
AGIO sits 43% above its 52-week low of $22.24.
Summary
Agios reported a third-quarter loss of $1.09 per share, a headline number that lands with the stock at $31.90 and the company valued at roughly $1.9 billion. The quarter's net loss narrowed to $65.0 million. The loss comes as the company is still spending heavily to launch AQVESME, which drove Q2 product revenue of $44.7 million, up 259% year-over-year. The bigger overhang remains regulatory: the FDA pushed the mitapivat sickle cell PDUFA date from November 1, 2026 to February 1, 2027, a three-month delay disclosed October 30. That decision is the binary event for the equity, and it now sits in the first quarter of next year. The quarter's loss per share is the first hard read on how much of the launch spend is hitting the income statement.
At the time of this announcement, AGIO was trading at $31.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.